Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Seeks partnership between government and private medical colleges for providing superior medical education
Allam was serving recently as the CEO at Public Investment Fund
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Subscribe To Our Newsletter & Stay Updated
